Alliancebernstein L.P. boosted its stake in Axovant Sciences (NASDAQ:AXON) by 108.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 108,600 shares of the biotechnology company’s stock after acquiring an additional 56,600 shares during the period. Alliancebernstein L.P. owned 0.10% of Axovant Sciences worth $572,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in the stock. Cubist Systematic Strategies LLC bought a new position in shares of Axovant Sciences during the 3rd quarter worth approximately $117,000. Virtus Fund Advisers LLC bought a new position in shares of Axovant Sciences during the 4th quarter worth approximately $349,000. Wells Fargo & Company MN boosted its holdings in shares of Axovant Sciences by 135.6% during the 3rd quarter. Wells Fargo & Company MN now owns 53,695 shares of the biotechnology company’s stock worth $369,000 after buying an additional 30,905 shares in the last quarter. Hikari Power Ltd bought a new position in shares of Axovant Sciences during the 4th quarter worth approximately $377,000. Finally, Ameriprise Financial Inc. boosted its holdings in shares of Axovant Sciences by 560.5% during the 3rd quarter. Ameriprise Financial Inc. now owns 192,909 shares of the biotechnology company’s stock worth $1,327,000 after buying an additional 163,704 shares in the last quarter. Institutional investors and hedge funds own 93.03% of the company’s stock.
A number of equities analysts have issued reports on AXON shares. Zacks Investment Research upgraded Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a report on Wednesday, January 31st. Jefferies Group cut Axovant Sciences from a “buy” rating to a “hold” rating and set a $6.00 price target on the stock. in a report on Thursday, December 21st. Cowen reiterated a “hold” rating on shares of Axovant Sciences in a report on Tuesday, February 13th. Oppenheimer reiterated a “hold” rating on shares of Axovant Sciences in a report on Tuesday, February 13th. Finally, Chardan Capital upgraded Axovant Sciences from a “sell” rating to a “neutral” rating and set a $2.50 target price on the stock in a report on Wednesday, January 10th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $13.61.
In other news, Director George Bickerstaff bought 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The shares were bought at an average cost of $1.50 per share, for a total transaction of $37,500.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 72.40% of the stock is owned by company insiders.
Shares of AXON opened at $1.17 on Tuesday. Axovant Sciences has a 12-month low of $1.14 and a 12-month high of $27.98. The company has a current ratio of 4.58, a quick ratio of 4.58 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $128.27, a P/E ratio of -0.64 and a beta of -0.40.
ILLEGAL ACTIVITY WARNING: “Alliancebernstein L.P. Has $572,000 Position in Axovant Sciences (AXON)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/17/alliancebernstein-l-p-has-572000-position-in-axovant-sciences-axon.html.
About Axovant Sciences
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia.
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axovant Sciences (NASDAQ:AXON).
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.